NAD+ infusions are among the most marketed services in wellness right now, and among the most loosely described. The claims run from energy and focus to cellular repair, longevity and addiction recovery.
The infusion itself is a medical act with an ordinary compliance profile. The claims are where clinics get into trouble.
The clinical basics
An NAD+ infusion is an intravenous administration requiring an order from a licensed provider, administration by appropriately licensed staff, and everything an IV service requires — evaluation, protocol, sterile technique, and an adverse event plan.
Two practical points come up constantly:
- Infusion rate matters. NAD+ is commonly associated with infusion-rate-related discomfort — chest tightness, nausea, flushing. Protocols should specify rate and titration, and staff should know how to respond.
- Sourcing matters. Preparations are typically compounded, which raises the same 503A versus 503B questions as anything else you infuse.
The claims problem
NAD+ marketing routinely asserts outcomes that available evidence does not support. Statements that create exposure:
| Common claim | Problem |
|---|---|
| “Reverses aging” | Unsupported; also a disease-adjacent claim |
| “Repairs DNA” | Mechanistic language presented as a clinical outcome |
| “Treats addiction” | Names a condition — this is a drug claim |
| “Cures chronic fatigue” | Names a condition and promises a cure |
| “Boosts metabolism by X%” | A quantified claim you must be able to substantiate |
| “FDA approved” | Compounded preparations are not FDA-approved products |
The distinction that matters: describing what a substance is and what patients commonly report is different from claiming it treats a condition. The moment you name a disease, you are making a drug claim.
Wellness framing does not exempt you
Operators often assume that positioning a service as “wellness” rather than “medical” lowers the bar. It does the opposite of what they hope — the service is still the practice of medicine because it requires an order and an infusion, while the marketing claims are judged on whether they are substantiated regardless of the label.
You get the regulatory obligations of medicine and no relief on advertising.
Writing it defensibly
A pattern that holds up:
“NAD+ is a coenzyme involved in cellular energy metabolism. We offer NAD+ infusions as an elective wellness service following evaluation by a licensed provider. Individual responses vary, and NAD+ infusions are not approved to treat, cure, or prevent any disease.”
That sentence costs nothing in conversion and removes most of the exposure.
Operational essentials
- Evaluation before the first infusion, and again on a material change in health
- Written protocol specifying formulation, rate, titration, and monitoring
- Staff trained on rate-related reactions and what to do
- Documented sourcing with the pharmacy’s basis confirmed
- Adverse event plan with a reachable provider
- Records showing why this patient was appropriate
Where MDside fits
We provide the ordering providers, write protocols to your actual formulary including infusion rates and reaction response, confirm pharmacy sourcing, and review the claims on the pages describing the service — because the marketing is a compliance surface, not a separate department.
See what is included, or read about IV therapy requirements.
Frequently asked questions
Do I need a provider order for an NAD+ infusion?
Yes. It is an infusion requiring an order from a licensed provider and administration by appropriately licensed staff under protocol.
Can I say NAD+ reverses aging?
No. That claim is unsupported and reads as a therapeutic claim. Describe what the substance is and note that responses vary.
Is NAD+ FDA approved?
Preparations used for infusion are typically compounded, and compounded preparations are not FDA-approved products.
Why do patients get chest tightness during infusion?
Rate-related reactions are commonly reported with NAD+ infusions. Protocols should specify rate and titration, and staff should be trained to slow or stop and escalate.
Can I market it for addiction recovery?
Naming a condition converts the statement into a drug claim about a product that is not approved to treat it. Do not.
General information, not medical or legal advice, and not a treatment recommendation. Confirm marketing claims with healthcare counsel and clinical protocols with your medical director.